Hung David 4

What Happened
David Hung, a director of NovoCure Ltd. (NVCR), was granted equity awards on June 3, 2026: 11,610 restricted stock units (RSUs) and 16,999 derivative awards (options). Both awards were reported at $0.00 per share, with a reported acquisition value of $0.

Key Details

• Transaction date(s): 2026-06-03; Form 4 filed: 2026-06-05 (timely—filed within the normal two-business-day window).
• Reported acquisitions: 11,610 shares (RSUs) and 16,999 derivative awards (options) at $0.00; total reported value $0.
• Shares owned after transaction: Not specified in the filing.
• Footnotes / vesting:
  • F1: The 11,610 RSUs are scheduled to vest 100% on the earlier of (i) the first anniversary of the grant or (ii) the day before the Company’s 2027 annual general meeting.
  • F2: The 16,999 derivative awards are options that will fully vest and become exercisable on the earlier of (i) the first anniversary of the grant or (ii) the day before the Company’s 2027 annual general meeting.
• Transaction code: A = Grant/Award.

Context
RSUs represent a promise to deliver shares upon vesting; the derivative awards are options that give the holder the right to buy shares once vested and exercisable. These grants involved no cash outlay at grant and do not represent an immediate sale or purchase of shares. As routine executive/director compensation, such awards are common and provide future equity incentives rather than an immediate market signal.